Patients-Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada

详细信息    查看全文

• 作者：Mark Oremus (1)
  Jean-Eric Tarride (1)
  Eleanor Pullenayegum (1) (2)
  Natasha Clayton (1)
  Parminder Raina (1)
  
• 刊名：The Patient - Patient-Centered Outcomes Research
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：6
• 期：3
• 页码：161-168
• 全文大小：273 KB
• 参考文献：1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137-2. CrossRef
  2. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344(15):1111-. CrossRef
  3. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-7. CrossRef
  4. Diagnostic and Statistical Manual of Mental Disorders. Text Revision (DSM-IV-TR), vol. 4. Arlington: American Psychiatric Association; 2000.
  5. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939-4. CrossRef
  6. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4(Suppl 1):55-9. CrossRef
  7. Dieckmann L, Zarit SH, Zarit JM, Gatz M. The Alzheimer’s disease knowledge test. Gerontologist. 1988;28(3):402-. CrossRef
  8. Alzheimer Society of Canada. Drugs approved for Alzheimer’s disease (online). http://www.alzheimer.ca/en/Living-with-dementia/Treatment-options/Drugs-approved-for-Alzheimers-disease. Accessed 9 Nov 2012.
  9. Bank of Canada. Monthly and annual average exchange rates (online). http://www.bankofcanada.ca/rates/exchange/exchange-rates-in-pdf/. Accessed 9 Nov 2012.
  10. Oremus M, Tarride JE, Raina P, et al. The general public’s willingness-to-pay for tax increases to support unrestricted access to an Alzheimer’s disease medication. Pharmacoeconomics. 2012;30(11):1085-5. CrossRef
  11. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-. CrossRef
  12. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987. CrossRef
  13. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-. CrossRef
  14. Konig M, Zweifel P. Willingness-to-pay against dementia: effects of altruism in between patients and their spouse caregivers. Socioeconomic Institute-working paper no. 0410. Zurich: University of Zurich; 2004.
  15. Wu G, Lanctot KL, Herrmann N, et al. The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach. CNS Drugs. 2003;17(14):1045-7. CrossRef
  16. Werner P, Schnaider-Beeri M, Aharon J, et al. Family caregivers-willingness to pay for drugs indicated for the treatment of Alzheimer’s disease: an economic or psychological model? Dementia. 2002;1(1):59-4. CrossRef
  17. Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics. 2008;26(8):661-7. CrossRef
  18. O’Brien B, Viramontes JL. Willingness to pay: a valid and reliable measure of health state preference? Med Decis Making. 1994;14(3):289-7. CrossRef
  19. Carpenter BD, Balsis S, Otilingam PG, et al. The Alzheimer’s Disease Knowledge Scale: development and psychometric properties. Gerontologist. 2009;49(2):236-7. CrossRef
  20. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
  21. Bryan S, Dolan P. Discrete choice experiments in health economics. For better or for worse? Eur J Health Econ. 2004;5(3):199-02. CrossRef
  22. Bayoumi AM. The measurement of contingent valuation for health economics. Pharmacoeconomics. 2004;22(11):691-00. CrossRef
  
• 作者单位：Mark Oremus (1)
  Jean-Eric Tarride (1)
  Eleanor Pullenayegum (1) (2)
  Natasha Clayton (1)
  Parminder Raina (1)
  
  1. Department of Clinical Epidemiology and Biostatistics, McMaster University DTC, 50 Main Street East, 3rd Floor, Hamilton, ON, L8N 1E9, Canada
  2. Biostatistical Unit, Centre for Evaluation of Medicines, McMaster University, Hamilton, ON, Canada
  

文摘

Background Alzheimer’s disease (AD) is a neurodegenerative disorder highlighted by progressive declines in cognition and function. Objectives The aim of this article is to assess whether persons with AD would support out-of-pocket payment for an AD medication; to elicit the monthly dollar amounts they would pay. Methods We recruited persons with mild or moderate AD (n?=?216) from nine clinics across Canada. During one-on-one interviews, we presented our sample with four scenarios describing a medication that either treated disease symptoms or modified the course of AD; each version of the medication was alternatively presented as having a 0?% or 30?% chance of adverse effects. For each scenario, participants indicated whether they would support paying out-of-pocket for the medication (yes/no). Affirmative responses were followed with questions asking participants whether they would pay $75, $150, or $225 (Canadian dollars) per month. Results Levels of support (‘yes-responses) ranged from 57?% to 83?% and mean willingness-to-pay ranged from $98 to $137, depending on scenario. Participants were more likely to provide affirmative responses and higher willingness-to-pay amounts when the medication modified disease or had a 0?% chance of adverse effects. Age was inversely associated with support in three scenarios and willingness-to-pay amounts in all four scenarios. Positive associations between post-secondary education and willingness-to-pay amounts were found in three scenarios. Conclusions Persons with mild or moderate AD were often willing to pay out-of-pocket for AD medications. However, the mean maximum willingness-to-pay ($137) for the optimal medication scenario was lower than the average monthly cost of existing AD medications.